Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2927436 | 1.00 | HRH3 (0.53) | HRH3POLBSRD5A1LMNAMAPT | |
| SCHEMBL2929162 | 0.88 | HRH3 (0.54) | HRH3POLBLMNAMAPTKMT2A | |
| SCHEMBL2929160 | 0.88 | HRH3 (0.54) | HRH3POLBLMNAMAPTKMT2A | |
| SCHEMBL2929881 | 0.87 | HRH3 (0.48) | HRH3POLBLMNAMAPTKMT2A | |
| SCHEMBL2929879 | 0.87 | HRH3 (0.48) | HRH3POLBLMNAMAPTKMT2A | |
| SCHEMBL2928768 | 0.86 | POLB (0.60) | HRH3POLBLMNAMAPTKMT2A | |
| SCHEMBL2928770 | 0.86 | POLB (0.60) | HRH3POLBLMNAMAPTKMT2A | |
| SCHEMBL2931784 | 0.85 | HRH3 (0.51) | HRH3POLBLMNAMAPTKMT2A | |
| SCHEMBL2931782 | 0.85 | HRH3 (0.51) | HRH3POLBLMNAMAPTKMT2A | |
| SCHEMBL4228646 | 0.85 | HRH3 (0.70) | HRH3SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2158189-B1 | CYCLOHEXYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | disclosed |
| EP-2158189-A1 | CYCLOHEXYL DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-03-03 | — | — | EP | disclosed |
| US-7544683-B2 | Cyclohexyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-06-09 | — | — | US | disclosed |
| WO-2008151957-A9 | CYCLOHEXYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-03-05 | — | — | WO | disclosed |
| US-20090005380-A1 | CYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-01 | — | — | US | disclosed |
| WO-2008151957-A1 | CYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005380-A1 | CYCLOHEXYL DERIVATIVES | HRH3, HRH4, HCAR2 | HRH3 1/4885POLB 4076/4885SRD5A1 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.